New drug targets KRAS mutations in advanced cancers

NCT ID NCT07094204

Recruiting now Disease control Sponsor: Astellas Pharma Inc Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing a new drug called ASP5834 in people with advanced solid tumors that have certain changes in the KRAS gene. The study will first find a safe dose of ASP5834 given alone or with another drug (panitumumab) in people with colorectal cancer. Up to 364 adults with lung, pancreatic, colorectal, or other solid tumors that haven't responded to standard treatment may participate. The main focus is on safety and tolerability, not yet on curing the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

ASP5834 (a drug targeting KRAS mutations) and panitumumab (a colorectal cancer drug)

What this could lead to

If this trial succeeds, it could point toward a new treatment option for people with advanced solid tumors that have specific KRAS mutations, especially those who haven't responded to standard therapies.

What could go wrong

This is a very early (Phase 1) study testing ASP5834 in humans for the first time. The main goal is safety and dosing, not yet effectiveness. Many early-stage drugs do not advance to later trials.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm neoplasm Neoplasm Metastasis non-small cell lung carcinoma pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER NON-SMALL-CELL LUNG CANCER PANCREATIC DUCTAL ADENOCARCINOMA SOLID TUMOR

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Cancer Institute Hospital of JFCR
RECRUITING

Koto-ku, Tokyo, Japan
Hackensack University Medical Center
RECRUITING

Hackensack, New Jersey, 07601, United States
Kansai Medical University Hospital
RECRUITING

Hirakata, Osaka, Japan
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
NEXT Oncology Dallas
RECRUITING

Irving, Texas, 75039, United States
NEXT Oncology Virginia
RECRUITING

Fairfax, Virginia, 22031, United States
Ochsner Health
RECRUITING

Jefferson, Louisiana, 70121, United States
Roswell Cancer Institute
RECRUITING

Buffalo, New York, 14263, United States
START Midwest
RECRUITING

Grand Rapids, Michigan, 49546, United States
Site ES34001
RECRUITING

Madrid, Spain
Site ES34003
RECRUITING

Madrid, Spain
Site ES34005
RECRUITING

Barcelona, Catalonia, Spain
Site FR33001
RECRUITING

Villejuif, France
Site FR33002
RECRUITING

Lyon, France
Site FR33003
RECRUITING

Bordeaux, New Aquitaine, France
Site FR33004
RECRUITING

Pierre-Bénite, France
UCLA Santa Monica Hematology Oncology
RECRUITING

Santa Monica, California, 90404, United States
University Hospitals - UH Cleveland Medical Center
RECRUITING

Cleveland, Ohio, 44106, United States
Washington University School of Medicine
RECRUITING

St Louis, Missouri, 63110, United States
Winship Cancer Institute at Emory University
RECRUITING

Atlanta, Georgia, 30322, United States